This episode explores alternative approval pathways for drugs addressing serious conditions, focusing on accelerated approval and breakthrough therapy designation. We discuss the criteria for these pathways, emphasizing the role of surrogate endpoints in accelerated approval and the requirement for confirmatory post-marketing studies. We explain how breakthrough therapy designation can significantly expedite drug development and review for serious or life-threatening conditions based on promising early clinical evidence. We also touch upon orphan drug designation as a separate pathway to incentivize the development of treatments for rare diseases. Join us as we delve into these accelerated pathways and their impact on bringing new treatments to patients faster.

This episode further examines the benefits and limitations of accelerated approv ...